{"id":"famotidine-fam","safety":{"commonSideEffects":[{"rate":"4-5%","effect":"Headache"},{"rate":"1-2%","effect":"Dizziness"},{"rate":"1-2%","effect":"Constipation"},{"rate":"1-2%","effect":"Diarrhea"},{"rate":"1%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":{"setId":"a2ef8424-7d80-42b0-a01e-f378f629b2b6","title":"PEPCID COMPLETE (FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE) TABLET, CHEWABLE [KENVUE BRANDS LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Famotidine competitively inhibits histamine binding to H2 receptors on gastric parietal cells, thereby decreasing both basal and stimulated gastric acid production. This reduction in acid secretion provides symptomatic relief and promotes healing of acid-related gastrointestinal lesions. It is more potent and longer-acting than earlier H2-receptor antagonists like cimetidine.","oneSentence":"Famotidine is a histamine H2-receptor antagonist that reduces gastric acid secretion by blocking histamine-mediated stimulation of parietal cells in the stomach.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:42.309Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Duodenal ulcer"},{"name":"Gastric ulcer"},{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Zollinger-Ellison syndrome"},{"name":"Peptic ulcer disease prophylaxis"}]},"trialDetails":[{"nctId":"NCT04545008","phase":"PHASE1","title":"Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19","status":"TERMINATED","sponsor":"Prisma Health-Upstate","startDate":"2020-10-20","conditions":"Covid19","enrollment":2},{"nctId":"NCT02684799","phase":"PHASE1","title":"Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination","status":"COMPLETED","sponsor":"Tobira Therapeutics, Inc.","startDate":"2016-01-31","conditions":"Healthy","enrollment":48},{"nctId":"NCT01232127","phase":"PHASE4","title":"Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-02","conditions":"HIV","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Famotidine (FAM)","genericName":"Famotidine (FAM)","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Famotidine is a histamine H2-receptor antagonist that reduces gastric acid secretion by blocking histamine-mediated stimulation of parietal cells in the stomach. Used for Duodenal ulcer, Gastric ulcer, Gastroesophageal reflux disease (GERD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}